Yueyang Zhou

Yueyang Zhou

Auto-generated profile, based on publicly available information

Yueyang Zhou

Center for Prevention and Early Intervention, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Mediators of Inflammation
Verified
Journal Article
Open access
CLChenyu Luo
Chenyu Luo
BTBowen Tian
Bowen Tian
YZYueyang Zhou
Yueyang Zhou
JLJiahui Luo
Jiahui Luo
QSQing Shang
Qing Shang
HCHongda Chen
Hongda Chen
Background: Patients with inflammatory bowel disease (IBD) have an elevated colorectal cancer (CRC) risk, though the etiology remains unclear. This study aimed to elucidate the interplay among IBD, gut microbiota (GM), inflammatory biomarkers, and CRC risk. Methods: First, we employed cohort analysis using the UK Biobank (UKB), linkage disequilibrium score regression (LDSC), and Mendelian randomization (MR) analyses to investigate the association between IBD and CRC. Second, inflammatory biomarkers’ indirect effect was assessed using mediation analysis. Third, the causal effects of IBD on GM and GM on inflammatory biomarkers were evaluated using MR. Finally, we constructed a disease severity biomarker score and evaluated its CRC risk stratification performance. Results: Among 441,321 participants, IBD was associated with a 1.78‐fold (95% confidence interval (CI): 1.45–2.18) increased risk of CRC. While LDSC and MR analyses showed no genetic correlation between IBD and CRC, mediation analyses revealed that C‐reactive protein (CRP) and neutrophil‐to‐lymphocyte ratio (NLR) significantly mediated 10.41% and 9.97% of the IBD–CRC association, respectively. IBD increased the GM abundance of Rikenellaceae RC9 gut group , and decreased Lactobacillaceae and Ruminococcus 2 , which in turn affected CRP, neutrophils, and lymphocytes. Notably, IBD decreased the abundance of Ruminococcus 2 after Bonferroni correction ( β = −9.463, p = 0.0002). A disease severity biomarker score comprising of CRP, platelets, platelet‐to‐lymphocyte ratio (PLR), NLR, hemoglobin (Hgb), and albumin was constructed. IBD patients with the highest scores had a 3.07‐fold (95% CI: 1.35–7.00) higher CRC risk compared to those with the lowest scores. Conclusions: IBD alters the microbial abundance of Rikenellaceae RC9 gut group , Lactobacillaceae , and Ruminococcus 2 , thereby, influencing inflammatory biomarkers including CRP, neutrophils, and lymphocytes, which mediate the increased risk of CRC in IBD patients. The constructed biomarker score enables individualized CRC risk stratification in IBD patients.